Stockholm, Sweden

Jingjing Li


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Inventor Spotlight: Jingjing Li**

Introduction

Jingjing Li, an innovative inventor based in Stockholm, Sweden, has made significant contributions to the field of biotechnology. With expertise in polypeptides, she has developed a noteworthy patent that addresses critical applications in medicine and diagnostics. Her work at Affibody AB exemplifies the intersection of science and technology.

Latest Patents

Jingjing Li holds a patent for "IGF-1R binding polypeptides and their use." This invention focuses on polypeptides that bind to the Insulin-like Growth Factor 1 Receptor (IGF-1R). The implications of her work extend to various applications within medicine and veterinary medicine, as well as in diagnostics and imaging, showcasing the versatility and potential impact of her research.

Career Highlights

Throughout her career, Jingjing has dedicated herself to advancing biochemical research, leveraging her understanding of polypeptide interactions. Her position at Affibody AB allows her to collaborate on pioneering projects that push the boundaries of medical science. This commitment not only enhances her career but also contributes to the advancement of healthcare solutions.

Collaborations

Jingjing works alongside skilled professionals such as Thomas Bergman and Anders Erik Jarstad at Affibody AB. This collaborative environment fosters innovation and the sharing of ideas, which is crucial in the fast-evolving field of biotechnology. Their joint efforts serve to accelerate research and the development of groundbreaking therapies.

Conclusion

Jingjing Li stands out as a remarkable inventor whose work is paving the way for future advancements in medicine and diagnostics. With her focus on IGF-1R binding polypeptides, she highlights the importance of innovation in addressing health challenges. As she continues her journey at Affibody AB, her contributions are sure to leave a lasting impact on the scientific community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…